Lipid-derived neutral nanoparticles
Disclosed herein are novel lipids and liposomal compositions prepared using such compounds and related methods of neutralizing or otherwise modifying such liposomal compositions. The lipids described herein are useful for example, as liposomal vehicles to facilitate the delivery of encapsulated polynucleotides to target cells and the subsequent transfection of such target cells. In certain embodiments, one or more of the compounds that comprise the liposomal delivery vehicle may be neutralized or further modified such that the properties of the liposomal delivery vehicle are modified.
1. A method of encapsulating mRNA in a neutral lipid nanoparticle, comprising the steps of:
(a) encapsulating one or more negatively charged nucleic acids within a lipid nanoparticle, wherein the lipid nanoparticle comprises:
a PEG-modified lipid;
one or more non-cationic lipids that is zwitterionic or anionic; and
one or more non-cationic lipids that is neutral;
a cationic lipid comprising a polar head-group bound to a lipophilic tail-group via a cleavable disulfide (S—S) linker group, wherein said cationic lipid is
(b) modulating the surface of the lipid nanoparticle by subjecting the linker group to chemical or enzymatic cleavage; thereby releasing the polar head-group from the surface of the lipid nanoparticle.
2. The method of claim 1 , wherein the modulating step comprises exposing the lipid nanoparticle to a reducing agent thereby cleaving the linker group and releasing the polar head-group from the lipophilic tail-group.
3. The method of claim 2 , wherein the reducing agent is tris (2-carboxyethyl)phosphine (TCEP), β-mercaptoethanol (β-ME), dithiothreitol (DTT), glutathione, dithioerythritol, or any combinations thereof.
4. The method of claim 1 , wherein the method results in an encapsulation efficiency of at least 65%.
5. The method of claim 1 , wherein the method results in an encapsulation efficiency of at least 75%.
6. The method of claim 1 , wherein the modulating step results in reducing the average zeta potential of the surface to less than about −0.5 mV.
7. The method of claim 1 , wherein the modulating step results in reducing the average zeta potential of the surface to between about −2.5 mV and +2.5 mV.
8. The method of claim 1 , wherein said cationic lipid is
9. The method of claim 1 , wherein said cationic lipid is
10. A composition comprising a lipid nanoparticle having an overall neutral surface charge and encapsulating negatively charged mRNA, wherein said lipid nanoparticle is made by a method comprising the steps of:
(a) encapsulating said negatively charged mRNA within a lipid nanoparticle, wherein the lipid nanoparticle comprises:
a PEG-modified lipid;
one or more non-cationic lipids that is zwitterionic or anionic;
one or more non-cationic lipids that is neutral; and
a cationic lipid comprising a polar head-group bound to a lipophilic tail-group via a cleavable disulfide (S—S) linker group, wherein said cationic lipid is
(b) exposing the lipid nanoparticle to chemical or enzymatic cleavage thereby releasing the polar head-group from the surface of the lipid nanoparticle to provide an overall neutral surface charge to the lipid nanoparticle.
11. The composition of claim 10 , wherein the encapsulation efficiency of step (a) is at least 65%.
12. The composition of claim 10 , wherein the encapsulation efficiency of step (a) is at least 75%.
13. The composition of claim 10 , wherein following step (b) the lipid nanoparticle has a surface charge or zeta potential of about −2.5 to about +2.5 mV.
14. The composition of claim 10 , wherein said mRNA encodes ornithine transcarbamylase (OTC), carbamoyl-phosphate synthetase 1 (CPS1), argininosuccinate synthetase (ASS1), argininosuccinate lyase (ASL), arginase 1 (ARG1), erythropoietin, human growth hormone, cystic fibrosis transmembrane conductance regulator (CFTR), alpha-L-iduronidase, N-acetylglucosaminidase, alpha-glucosaminide acetyltransferase, N-acetylglucosamine 6-sulfatase, N-acetylgalactosamine-4-sulfatase, galactose-6-sulfate sulfatase, beta-galactosidase, beta-glucuronidase, glucocerebrosidase, heparan sulfamidase, heparin-N-sulfatase, lysosomal acid lipase, acid alpha-glucosidase, arylsulfatase A, or hyaluronidase.
15. The composition of claim 10 , wherein
said one or more non-cationic lipids that is zwitterionic or anionic is: distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dipalmitoylphosphatidylcholine (DPPC), dioleoylphosphatidylethanolamine (DOPE), palmitoyloleoylphosphatidylcholine (POPC), palmitoyloleoyl-phosphatidylethanolamine (POPE), dioleoyl-phosphatidylethanolamine 4-(N-maleimidomethyl)-cyclohexane-1-carboxylate (DOPE-mal), dipalmitoyl phosphatidyl ethanolamine (DPPE), dimyristoylphosphoethanolamine (DMPE), distearoyl-phosphatidyl-ethanolamine (DSPE), DLPE (1,2-dilauroyl-sn-glycero-3-phosphoethanolamine), DPPS (1,2-dipalmitoyl-sn-glycero-3-phospho-L-serine), 16-O-monomethyl PE, 16-O-dimethyl PE, 18-1-trans PE, 1-stearoyl-2-oleoyl-phosphatidyethanolamine (SOPE), a sphingomyelin, or a mixture thereof;
and/or
said one or more non-cationic lipids that is neutral comprises cholesterol.
16. The composition of claim 10 , wherein said cationic lipid is
17. The composition of claim 10 , wherein said cationic lipid is
18. A pharmaceutical composition comprising a lipid nanoparticle having an overall neutral surface charge and encapsulating negatively charged mRNA,
wherein said lipid nanoparticle is made by a method comprising the steps of:
(a) encapsulating said negatively charged mRNA within a lipid nanoparticle,
wherein the lipid nanoparticle comprises:
a PEG-modified lipid;
one or more non-cationic lipids that is zwitterionic or anionic;
one or more non-cationic lipids that is neutral; and
a cationic lipid comprising a polar head-group bound to a lipophilic tail-group via a cleavable disulfide (S—S) linker group, wherein said cationic lipid is
(b) exposing the surface of the lipid nanoparticle to chemical or enzymatic cleavage thereby releasing the polar head-group from the surface of the lipid nanoparticle to provide an overall neutral surface to the lipid nanoparticle.
19. The pharmaceutical composition of claim 18 , wherein the encapsulation efficiency of step (a) is at least 65%.
20. The pharmaceutical composition of claim 18 , wherein the encapsulation efficiency of step (a) is at least 75%.
21. The pharmaceutical composition of claim 18 , wherein following step (b) the lipid nanoparticle has a surface charge or zeta potential of about −2.5 to about +2.5 mV.
22. The pharmaceutical composition of claim 18 , wherein said mRNA encodes ornithine transcarbamylase (OTC), carbamoyl-phosphate synthetase 1 (CPS1), argininosuccinate synthetase (ASS1), argininosuccinate lyase (ASL), arginase 1 (ARG1), erythropoietin, human growth hormone, cystic fibrosis transmembrane conductance regulator (CFTR), alpha-L-iduronidase, N-acetylglucosaminidase, alpha-glucosaminide acetyltransferase, N-acetylglucosamine 6-sulfatase, N-acetylgalactosamine-4-sulfatase, galactose-6-sulfate sulfatase, beta-galactosidase, beta-glucuronidase, glucocerebrosidase, heparan sulfamidase, heparin-N-sulfatase, lysosomal acid lipase, acid alpha-glucosidase, arylsulfatase A, or hyaluronidase.
23. The pharmaceutical composition of claim 18 , wherein
said one or more non-cationic lipids that is zwitterionic or anionic is: distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dipalmitoylphosphatidylcholine (DPPC), dioleoylphosphatidylethanolamine (DOPE), palmitoyloleoylphosphatidylcholine (POPC), palmitoyloleoyl-phosphatidylethanolamine (POPE), dioleoyl-phosphatidylethanolamine 4-(N-maleimidomethyl)-cyclohexane-1-carboxylate (DOPE-mal), dipalmitoyl phosphatidyl ethanolamine (DPPE), dimyristoylphosphoethanolamine (DMPE), distearoyl-phosphatidyl-ethanolamine (DSPE), DLPE (1,2-dilauroyl-sn-glycero-3-phosphoethanolamine), DPPS (1,2-dipalmitoyl-sn-glycero-3-phospho-L-serine), 16-O-monomethyl PE, 16-O-dimethyl PE, 18-1-trans PE, 1-stearoyl-2-oleoyl-phosphatidyethanolamine (SOPE), a sphingomyelin, or a mixture thereof;
and/or
said one or more non-cationic lipids that is neutral comprises cholesterol.
24. The pharmaceutical composition of claim 18 , wherein said cationic lipid is
25. The pharmaceutical composition of claim 18 , wherein said cationic lipid is